Mechanistic Insights into the Impact of Cigarette Smoking on Glycemic Control and Metabolic Health

Keywords: Cigarette Smoking, Glycemic Control, Insulin Resistance, Type 2 Diabetes, Metabolic Dysfunction

Introduction

Cigarette smoking remains one of the most significant modifiable risk factors contributing to global morbidity and mortality, with well-established associations with cardiovascular disease, malignancy, and chronic respiratory conditions. Despite extensive research on its pulmonary and vascular effects, the metabolic consequences of smoking have received comparatively less emphasis in both clinical practice and public health discourse.

Recent evidence has increasingly highlighted the role of smoking in disrupting glucose homeostasis. Smoking has been associated with impaired glycemic control, increased insulin resistance, and a heightened risk of developing type 2 diabetes mellitus (T2DM). These metabolic disturbances are particularly relevant given the rising global burden of diabetes and its complications.

In the context of preventive medicine and longevity-focused care, early identification of modifiable factors that contribute to metabolic dysfunction is essential. Smoking represents a critical yet often underrecognized driver of early dysglycemia, preceding the onset of overt metabolic disease. A deeper understanding of the underlying mechanisms linking smoking to glucose dysregulation may inform more comprehensive strategies for risk reduction and health optimization.

Pathophysiological Mechanisms Linking Smoking and Blood Glucose Dysregulation

The relationship between cigarette smoking and blood glucose regulation is mediated by multiple, interrelated pathophysiological pathways, involving acute neurohormonal responses as well as chronic molecular and cellular adaptations. These mechanisms encompass sympathetic nervous system activation, systemic inflammation, oxidative stress, alterations in insulin signalling, and adipose tissue dysfunction, ultimately converging on insulin resistance and dysglycemia [1,2].

Nicotine, the primary pharmacologically active component of cigarettes, plays a central role in acute metabolic perturbations. By stimulating the release of catecholamines, particularly epinephrine and norepinephrine—nicotine enhances sympathetic nervous system activity, which in turn promotes hepatic gluconeogenesis and glycogenolysis, leading to elevated circulating glucose levels. Simultaneously, catecholamine excess and nicotine exposure impair insulin-mediated glucose uptake in peripheral tissues, particularly skeletal muscle, thereby contributing to reduced insulin sensitivity. Experimental data in humans and cell models show that nicotine can directly decrease insulin sensitivity, and that partial reversal occurs following smoking cessation, underscoring a causal and at least partially reversible link between nicotine exposure and impaired insulin action [1,3-5].

Beyond these acute neurohormonal effects, chronic smoking is associated with systemic inflammation and oxidative stress, both of which interfere with insulin signalling pathways. Smokers exhibit elevated levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which are known to disrupt insulin receptor signalling, including via inhibitory phosphorylation of insulin receptor substrate-1 (IRS-1). Skeletal muscle biopsies from chronic smokers demonstrate increased serine phosphorylation of IRS-1 at Ser636, a modification associated with impaired downstream insulin signalling and insulin resistance; this abnormal phosphorylation pattern improves after smoking cessation. Concurrently, cigarette-smoke–induced oxidative stress, characterized by elevated reactive oxygen species (ROS), contributes to lipid peroxidation, protein and DNA damage, and may impair pancreatic beta-cell function as well as peripheral insulin action [2,3].

Adipose tissue represents another key target of smoking-related metabolic disruption. Smoking has been shown to alter adipokine secretion, particularly by reducing circulating adiponectin levels, an adipokine that enhances insulin sensitivity through activation of AMP-activated protein kinase (AMPK) in liver and skeletal muscle. Clinical studies report that smokers, especially non-obese smokers, have significantly lower adiponectin concentrations compared with non-smokers, suggesting an adverse shift in adipose tissue endocrine function even in the absence of overt obesity. In parallel, smoking is associated with unfavourable body fat distribution, with a relative increase in visceral adiposity despite lower or similar overall body weight, thereby promoting ectopic fat accumulation, lipotoxicity, and further worsening of insulin resistance [1-3,6].

Additional mechanistic insights point to potential epigenetic and transcriptional effects of smoking on metabolic pathways. Smoking has been linked to decreased expression of peroxisome proliferator-activated receptor-gamma (PPAR-γ), a transcription factor that promotes insulin sensitivity, as well as to altered DNA methylation patterns in genes involved in insulin receptor binding and negative regulation of glucose import. Together, these findings suggest that smoking-induced disturbances in glucose metabolism arise not only from acute catecholamine surges and inflammatory signalling, but also from longer-term remodelling of insulin signalling networks and adipose tissue biology. Collectively, these pathophysiological mechanisms provide a coherent framework through which cigarette smoking contributes to insulin resistance, impaired glycemic control, and increased risk of type 2 diabetes mellitus [2,9].

Impact on Glycemic Control and Diabetes Risk

Epidemiological data consistently indicate that active cigarette smoking is associated with a higher risk of developing type 2 diabetes mellitus (T2DM) compared with never smoking. Large cohort and meta-analytic studies have shown that current smokers have approximately a 30–40% increased risk of incident T2DM after adjustment for conventional risk factors, including age, adiposity, and lifestyle variables. The excess risk appears to be at least partly dose-dependent, with heavier cumulative exposure (for example, higher pack-years) correlating with greater diabetes risk and more pronounced metabolic impairment [2,7-9].

Among individuals with established diabetes, smoking has a detrimental impact on glycemic control. Observational studies from national diabetes registries and real-world cohorts report that smokers with T2DM have higher mean HbA1c levels and are more likely to exhibit poor glycemic control (commonly defined as HbA1c ≥7%) compared with non-smokers. For instance, in a large cohort of men with newly diagnosed T2DM, smoking was associated with a significantly increased odds of poor glycemic control and a smaller reduction in HbA1c over 12 months of follow-up, with mean HbA1c differences on the order of 0.25–0.3 percentage points between smokers and never-smokers. In people with type 1 diabetes, smoking has similarly been linked to inadequate glycemic control and increased glycemic variability on continuous glucose monitoring, including more time spent in hyperglycemia and reduced time in target range [10,11].

These adverse glycemic patterns may translate into more complex therapeutic needs. Smoking has been associated with reduced responsiveness to insulin therapy and potentially diminished effectiveness of oral hypoglycemic agents, necessitating higher doses and more intensive regimens to achieve comparable glycemic targets. In addition to worsening glycemic metrics, the combination of smoking and hyperglycemia appears to accelerate both microvascular and macrovascular complications, further amplifying overall diabetes-related risk [8,12,13].

The interplay between smoking cessation, weight change, and diabetes risk is more nuanced. Several prospective cohort studies have demonstrated that smoking cessation is frequently accompanied by short-term weight gain and a transient increase in T2DM incidence compared with continued smoking, particularly within the first 3–7 years after quitting. In pooled analyses of large cohorts, recent quitters showed a temporarily elevated hazard of T2DM relative to current smokers, largely mediated by post-cessation weight gain, with risk highest among those who gained ≥5 kg in the early years after quitting. Nonetheless, as time since cessation increases, diabetes risk gradually declines; after roughly 10 years of sustained abstinence, the risk of T2DM in former smokers often approaches that of never-smokers, especially in individuals who limit weight gain [7,14].

Long-term observational data therefore support the conclusion that, despite a short-term metabolic penalty related to weight gain, smoking cessation ultimately confers net benefit for glycemic health. Sustained abstinence is associated with improved insulin sensitivity, reduced chronic inflammation, and lower long-term risk of developing T2DM compared with continued smoking. These findings underscore the importance of integrating structured weight-management and lifestyle strategies into smoking-cessation programs for individuals at high metabolic risk, in order to maximize improvements in glycemic control and reduce the burden of diabetes over the life course [2,8,14].

Clinical Implications in Preventive and Longevity Medicine

From a preventive medicine standpoint, cigarette smoking should be conceptualized not only as a traditional cardiovascular and oncologic risk factor, but as a major driver of metabolic dysfunction, including metabolic syndrome, insulin resistance, and type 2 diabetes. Epidemiological data demonstrate that active smoking is associated with increased prevalence and incidence of metabolic syndrome and adverse changes in its components, such as abdominal obesity, hypertriglyceridemia, low HDL cholesterol, and elevated fasting glucose often emerging before overt cardiovascular disease. Consequently, systematic assessment of smoking status (current, former, never, and quantification by pack-years) should be integrated into routine metabolic risk stratification alongside fasting plasma glucose, HbA1c, lipid profile, blood pressure, and measures of central adiposity or body composition [2,15-18].

For clinicians practicing in longevity and wellness-focused settings, the recognition of smoking as a modifiable determinant of metabolic health has important therapeutic implications. Smoking cessation interventions have been shown to reduce cardiometabolic risk and confer meaningful gains in life expectancy, including in higher-risk populations such as patients with acute myocardial infarction and established cardiometabolic disease. In this context, smoking cessation can be framed as a high-yield lever to improve metabolic flexibility, decrease systemic inflammation, and slow the progression of metabolic syndrome and diabetes, thereby supporting both health span and lifespan goals [2,16,19,20].

The practical integration of these insights into clinical care may involve embedding structured tobacco-use assessment and cessation counselling into metabolic and diabetes clinics, cardiovascular prevention programs, and comprehensive longevity evaluations. Evidence-based strategies, such as behavioural counselling, pharmacotherapy (including nicotine replacement, varenicline, or bupropion), and digital or telehealth support—can be combined with concurrent lifestyle interventions targeting diet quality, physical activity, and weight management to offset post-cessation weight gain and optimize glycemic trajectories. Given that smoking appears to worsen the diagnostic characteristics and natural history of metabolic syndrome, early and aggressive intervention on tobacco use may prevent progression from subclinical metabolic alterations to overt diabetes and cardiovascular disease [14-16,19].

Emerging technologies also create opportunities to personalize risk communication and enhance patient engagement. The use of continuous glucose monitoring (CGM) in individuals with diabetes or prediabetes who smoke may provide real-time visualization of acute glycemic excursions related to smoking episodes, stress, and dietary patterns, potentially increasing risk awareness and motivation to quit. Similarly, metabolomic profiling studies suggest that smoking generates a distinct metabolic signature that partly mediates its association with type 2 diabetes, highlighting the potential for biomarker-based risk stratification and tailored preventive strategies in high-risk individuals, particularly those with underlying genetic susceptibility [8,12,20].

In longevity-oriented care models, integrating smoking status into composite risk scores, longitudinal biomarker panels, and “health span dashboards” can help prioritize interventions and track the impact of cessation on metabolic and vascular health over time. The convergence of epidemiologic, mechanistic, and clinical evidence supports positioning smoking cessation as a cornerstone intervention in metabolic and longevity medicine, warranting the same level of attention as glycemic control, lipid management, and blood pressure optimization in comprehensive preventive strategies [2,16,22].

Conclusion

Cigarette smoking exerts substantial adverse effects on glucose metabolism through a complex interplay of pathophysiological mechanisms, including sympathetic nervous system activation, chronic low-grade inflammation, oxidative stress, and dysregulation of adipokines. Collectively, these processes contribute to the development of insulin resistance, impaired glycemic control, and an increased risk of type 2 diabetes mellitus.

From a clinical perspective, recognizing smoking as a significant and modifiable determinant of metabolic dysfunction is essential. Its impact extends beyond traditional cardiopulmonary consequences, underscoring the need for a more integrated approach to risk assessment and management in patients at risk of metabolic disease.

In the setting of preventive medicine and longevity-focused care, targeted interventions that prioritize smoking cessation alongside metabolic optimization strategies may provide substantial benefits. Such approaches have the potential to reduce long-term morbidity and mortality while improving overall metabolic resilience and health span.

Reference

Sari MI, Sari N, Darlan DM, Prasetya RJ. Cigarette Smoking and Hyperglycaemia in Diabetic Patients. Open Access Macedonian Journal of Medical Sciences [Internet]. 2018 Apr 8;6(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927492/
Maddatu J, Anderson-Baucum E, Evans-Molina C. Smoking and the risk of type 2 diabetes. Translational Research : the Journal of Laboratory and Clinical Medicine [Internet]. 2017 Mar 6;184(184):101–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429867/
Bergman BC, Perreault L, Hunerdosse D, Kerege A, Playdon M, Samek AM, et al. Novel and Reversible Mechanisms of Smoking-Induced Insulin Resistance in Humans. Diabetes. 2012 Sep 10;61(12):3156–66.
Chen Z, Liu XA, Kenny PJ. Central and peripheral actions of nicotine that influence blood glucose homeostasis and the development of diabetes. Pharmacological Research. 2023 Aug 1;194:106860–0.
Bajaj M. Nicotine and Insulin Resistance: When the Smoke Clears. Diabetes [Internet]. 2012 Nov 21;61(12):3078–80. Available from: https://diabetes.diabetesjournals.org/content/61/12/3078
Reversible mechanism of smoking-induced insulin resistance. Nature Reviews Endocrinology. 2012 Oct 2;8(12):698–8.
Luo J, Rossouw J, Tong E, Giovino GA, Lee CC, Chen C, et al. Smoking and Diabetes: Does the Increased Risk Ever Go Away? American Journal of Epidemiology [Internet]. 2013 Jun 30 [cited 2019 Nov 25];178(6):937–45. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816526/
Campagna D, Alamo A, Di Pino A, Russo C, Calogero AE, Purrello F, et al. Smoking and diabetes: Dangerous liaisons and confusing relationships. Diabetology & Metabolic Syndrome [Internet]. 2019 Oct 24;11(1). Available from: https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-019-0482-2
Xie X, Liu Q, Wu J, Wakui M. Impact of cigarette smoking in type 2 diabetes development. Acta Pharmacologica Sinica [Internet]. 2009 May 11;30(6):784–7. Available from: https://www.nature.com/articles/aps200949
Sia HK, Kor CT, Tu ST, Liao PY, Wang JY. Association between smoking and glycemic control in men with newly diagnosed type 2 diabetes: a retrospective matched cohort study. Annals of Medicine. 2022 May 16;54(1):1385–94.
Jensen MH, Cichosz SL, Hirsch IB, Vestergaard P, Hejlesen O, Seto E. Smoking is Associated With Increased Risk of Not Achieving Glycemic Target, Increased Glycemic Variability, and Increased Risk of Hypoglycemia for People With Type 1 Diabetes. Journal of Diabetes Science and Technology. 2020 May 26;193229682092225.
Food and Drug Administration. How Smoking Can Increase Risk for and Affect Diabetes. FDA [Internet]. 2023 Dec 4; Available from: https://www.fda.gov/tobacco-products/health-effects-tobacco-use/how-smoking-can-increase-risk-and-affect-diabetes
Akkuzulu H, Aypak C, Özdemir A, Görpelioğlu S. Impact of smoking and nicotine addiction on HbA1c levels and diabetic microvascular complications. Clinical Diabetology. 2020 May 14;9(2):112–7.
Yeh HC. Smoking, Smoking Cessation, and Risk for Type 2 Diabetes Mellitus. Annals of Internal Medicine. 2010 Jan 5;152(1):10.
Behl TA, Stamford BA, Moffatt RJ. The Effects of Smoking on the Diagnostic Characteristics of Metabolic Syndrome: A Review. American Journal of Lifestyle Medicine. 2022 Jun 28;17(3):155982762211110.
Sun K, Liu J, Ning G. Active Smoking and Risk of Metabolic Syndrome: A Meta-Analysis of Prospective Studies. Barengo NC, editor. PLoS ONE. 2012 Oct 17;7(10):e47791.
Valmore Bermúdez, Luis Carlos Olivar, Torres W, Navarro C, Robys González, Espinoza I, et al. Cigarette smoking and metabolic syndrome components: a cross-sectional study from Maracaibo City, Venezuela. F1000Research. 2019 Jan 11;7:565–5.
Oh SW, Yoon YS, Lee ES, Kim WK, Park C, Lee S, et al. Association between cigarette smoking and metabolic syndrome: the Korea National Health and Nutrition Examination Survey. Diabetes Care [Internet]. 2005 Aug 1 [cited 2021 Jan 28];28(8):2064–6. Available from: https://pubmed.ncbi.nlm.nih.gov/16043763/
Bucholz EM, Beckman AL, Kiefe CI, Krumholz HM. Life Years Gained From Smoking-Cessation Counseling After Myocardial Infarction. American Journal of Preventive Medicine. 2017 Jan;52(1):38–46.
Wei Y, Hägg S, Jonathan, Tuomi T, Zhan Y, Carlsson S. Metabolic profiling of smoking, associations with type 2 diabetes and interaction with genetic susceptibility. European Journal of Epidemiology. 2024 Mar 31;39(6):667–78.
Zhang J, Hou L, Lei S, Li Y, Xu G. The causal relationship of cigarette smoking to metabolic disease risk and the possible mediating role of gut microbiota. Ecotoxicology and Environmental Safety. 2024 Dec 21;290:117522–2.
Valmore Bermúdez, Luis Carlos Olivar, Torres W, Navarro C, Robys González, Espinoza I, et al. Cigarette smoking and metabolic syndrome components: a cross-sectional study from Maracaibo City, Venezuela. F1000Research. 2019 Jan 11;7:565–5.